Skip to content

Clinical trials

Stomach Neoplasms trials in South Korea

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Stomach Neoplasms Country / region: South Korea Clear all

476 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20021
20038
20046
20054
200614
200711
200811
200918
201028
201122
201230
201321
201422
201527
201623
201721
201819
201927
202034
202132
202229
202320
202416
202516
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed241
Unknown status100
Recruiting55
Active, not recruiting34
Terminated30
Withdrawn9
Not yet recruiting6
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Yonsei University62
National Cancer Center, Korea34
Samsung Medical Center30
Asan Medical Center27
Seoul National University Bundang Hospital22
Seoul National University Hospital18
AstraZeneca15
Gangnam Severance Hospital12
Hoffmann-La Roche10
Ajou University School of Medicine8

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Stomach Neoplasms476
Colorectal Neoplasms32
Breast Neoplasms31
Esophageal Neoplasms27
Neoplasms27
Carcinoma, Non-Small-Cell Lung25
Neoplasm Metastasis25
Ovarian Neoplasms22
Pancreatic Neoplasms22
Biliary Tract Neoplasms15

Trials

Showing 1 to 25 of 476. Each trial links to its page on Pharma Observatory.

376 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.